Medical - Devices
Compare Stocks
5 / 10Stock Comparison
SSII vs RBOT vs ISRG vs MASI vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Devices
SSII vs RBOT vs ISRG vs MASI vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $763M | $3M | $161.07B | $9.35B | $99.94B |
| Revenue (TTM) | $42M | $0.00 | $10.58B | $1.56B | $35.48B |
| Net Income (TTM) | $-12M | $-42M | $2.98B | $76M | $4.61B |
| Gross Margin | 46.0% | — | 66.3% | 61.7% | 61.9% |
| Operating Margin | -19.2% | — | 30.5% | 19.9% | 17.9% |
| Forward P/E | — | — | 43.8x | 32.5x | 14.1x |
| Total Debt | $3M | $8M | $303M | $559M | $28.52B |
| Cash & Equiv. | $3M | $3M | $3.37B | $152M | $2.22B |
SSII vs RBOT vs ISRG vs MASI vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| SS Innovations Inte… (SSII) | 100 | 714.5 | +614.5% |
| Vicarious Surgical … (RBOT) | 100 | 0.2 | -99.8% |
| Intuitive Surgical,… (ISRG) | 100 | 191.7 | +91.7% |
| Masimo Corporation (MASI) | 100 | 75.6 | -24.4% |
| Medtronic plc (MDT) | 100 | 75.0 | -25.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SSII vs RBOT vs ISRG vs MASI vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SSII is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 105.7%, EPS growth 40.0%, 3Y rev CAGR 207.7%
- Lower volatility, beta 0.01, Low D/E 7.6%, current ratio 1.86x
- Beta 0.01, current ratio 1.86x
- 105.7% revenue growth vs MASI's -27.1%
Among these 5 stocks, RBOT doesn't own a clear edge in any measured category.
ISRG ranks third and is worth considering specifically for long-term compounding and valuation efficiency.
- 5.5% 10Y total return vs SSII's 162.0%
- PEG 2.01 vs MDT's 36.00
- 28.2% margin vs SSII's -28.5%
MASI is the clearest fit if your priority is momentum.
- +18.9% vs RBOT's -94.1%
MDT carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Lower P/E (14.1x vs 32.5x)
- 3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend
- 175.8% ROA vs RBOT's -164.5%, ROIC 6.0% vs -116.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 105.7% revenue growth vs MASI's -27.1% | |
| Value | Lower P/E (14.1x vs 32.5x) | |
| Quality / Margins | 28.2% margin vs SSII's -28.5% | |
| Stability / Safety | Beta 0.01 vs RBOT's 1.92, lower leverage | |
| Dividends | 3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +18.9% vs RBOT's -94.1% | |
| Efficiency (ROA) | 175.8% ROA vs RBOT's -164.5%, ROIC 6.0% vs -116.2% |
SSII vs RBOT vs ISRG vs MASI vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SSII vs RBOT vs ISRG vs MASI vs MDT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MDT leads in 2 of 6 categories
ISRG leads 1 • SSII leads 1 • RBOT leads 0 • MASI leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT and RBOT operate at a comparable scale, with $35.5B and $0 in trailing revenue. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to SSII's -28.5%. On growth, SSII holds the edge at +158.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $42M | $0 | $10.6B | $1.6B | $35.5B |
| EBITDAEarnings before interest/tax | -$7M | -$42M | $3.8B | $340M | $9.4B |
| Net IncomeAfter-tax profit | -$12M | -$42M | $3.0B | $76M | $4.6B |
| Free Cash FlowCash after capex | -$22M | -$40M | $2.8B | $211M | $5.4B |
| Gross MarginGross profit ÷ Revenue | +46.0% | — | +66.3% | +61.7% | +61.9% |
| Operating MarginEBIT ÷ Revenue | -19.2% | — | +30.5% | +19.9% | +17.9% |
| Net MarginNet income ÷ Revenue | -28.5% | — | +28.2% | +4.9% | +13.0% |
| FCF MarginFCF ÷ Revenue | -52.3% | — | +26.8% | +13.6% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +158.4% | — | +23.0% | +8.5% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +69.0% | +58.1% | +18.8% | +134.4% | -11.9% |
Valuation Metrics
MDT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, MDT trades at a 63% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), ISRG offers better value at 2.65x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $763M | $3M | $161.1B | $9.3B | $99.9B |
| Enterprise ValueMkt cap + debt − cash | $763M | $8M | $158.0B | $9.8B | $126.2B |
| Trailing P/EPrice ÷ TTM EPS | -65.50x | -0.06x | 57.62x | -63.75x | 21.60x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 43.84x | 32.46x | 14.13x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.65x | — | 36.00x |
| EV / EBITDAEnterprise value multiple | — | — | 43.62x | 27.74x | 14.32x |
| Price / SalesMarket cap ÷ Revenue | 17.96x | — | 16.00x | 6.12x | 2.98x |
| Price / BookPrice ÷ Book value/share | 20.43x | 0.30x | 9.17x | 13.41x | 2.08x |
| Price / FCFMarket cap ÷ FCF | — | — | 64.67x | 47.26x | 19.28x |
Profitability & Efficiency
Evenly matched — ISRG and MASI each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-3 for RBOT. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to RBOT's 0.79x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs RBOT's 1/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -30.2% | -3.3% | +16.9% | +9.1% | +9.4% |
| ROA (TTM)Return on assets | -17.5% | -164.5% | +14.8% | +4.0% | +175.8% |
| ROICReturn on invested capital | -17.7% | -116.2% | +15.0% | +16.5% | +6.0% |
| ROCEReturn on capital employed | -23.6% | -134.6% | +16.5% | +18.8% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 1 | 6 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.08x | 0.79x | 0.02x | 0.78x | 0.59x |
| Net DebtTotal debt minus cash | -$289,540 | $5M | -$3.1B | $407M | $26.3B |
| Cash & Equiv.Liquid assets | $3M | $3M | $3.4B | $152M | $2.2B |
| Total DebtShort + long-term debt | $3M | $8M | $303M | $559M | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | -7.35x | — | — | 12.50x | 9.08x |
Total Returns (Dividends Reinvested)
SSII leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SSII five years ago would be worth $38,155 today (with dividends reinvested), compared to $16 for RBOT. Over the past 12 months, MASI leads with a +18.9% total return vs RBOT's -94.1%. The 3-year compound annual growth rate (CAGR) favors SSII at 82.1% vs RBOT's -80.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -30.4% | -80.6% | -19.3% | +40.1% | -18.1% |
| 1-Year ReturnPast 12 months | -61.3% | -94.1% | -15.4% | +18.9% | -2.8% |
| 3-Year ReturnCumulative with dividends | +503.7% | -99.2% | +49.6% | -4.9% | -4.2% |
| 5-Year ReturnCumulative with dividends | +281.6% | -99.8% | +58.7% | -20.4% | -27.7% |
| 10-Year ReturnCumulative with dividends | +162.0% | -99.8% | +554.2% | +282.9% | +26.5% |
| CAGR (3Y)Annualised 3-year return | +82.1% | -80.2% | +14.4% | -1.7% | -1.4% |
Risk & Volatility
Evenly matched — SSII and MASI each lead in 1 of 2 comparable metrics.
Risk & Volatility
SSII is the less volatile stock with a 0.01 beta — it tends to amplify market swings less than RBOT's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MASI currently trades 99.7% from its 52-week high vs RBOT's 3.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.01x | 1.92x | 1.02x | 0.63x | 0.47x |
| 52-Week HighHighest price in past year | $11.87 | $13.75 | $603.88 | $179.10 | $106.33 |
| 52-Week LowLowest price in past year | $3.02 | $0.35 | $427.84 | $125.94 | $77.16 |
| % of 52W HighCurrent price vs 52-week peak | +33.1% | +3.6% | +75.1% | +99.7% | +73.3% |
| RSI (14)Momentum oscillator 0–100 | 39.1 | 30.0 | 42.4 | 63.8 | 27.3 |
| Avg Volume (50D)Average daily shares traded | 54K | 24K | 1.8M | 1.2M | 7.8M |
Analyst Outlook
MDT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ISRG as "Buy", MASI as "Buy", MDT as "Buy". Consensus price targets imply 40.5% upside for MDT (target: $110) vs 5.0% for MASI (target: $188). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $622.60 | $187.50 | $109.50 |
| # AnalystsCovering analysts | — | — | 55 | 23 | 49 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +3.6% |
| Dividend StreakConsecutive years of raises | — | — | — | 0 | 36 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.4% | +3.9% | +3.2% |
MDT leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). ISRG leads in 1 (Income & Cash Flow). 2 tied.
SSII vs RBOT vs ISRG vs MASI vs MDT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SSII or RBOT or ISRG or MASI or MDT a better buy right now?
For growth investors, SS Innovations International, Inc.
(SSII) is the stronger pick with 105. 7% revenue growth year-over-year, versus -27. 1% for Masimo Corporation (MASI). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SSII or RBOT or ISRG or MASI or MDT?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
6x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Intuitive Surgical, Inc. wins at 2. 01x versus Medtronic plc's 36. 00x.
03Which is the better long-term investment — SSII or RBOT or ISRG or MASI or MDT?
Over the past 5 years, SS Innovations International, Inc.
(SSII) delivered a total return of +281. 6%, compared to -99. 8% for Vicarious Surgical Inc. (RBOT). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus RBOT's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SSII or RBOT or ISRG or MASI or MDT?
By beta (market sensitivity over 5 years), SS Innovations International, Inc.
(SSII) is the lower-risk stock at 0. 01β versus Vicarious Surgical Inc. 's 1. 92β — meaning RBOT is approximately 13245% more volatile than SSII relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 79% for Vicarious Surgical Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SSII or RBOT or ISRG or MASI or MDT?
By revenue growth (latest reported year), SS Innovations International, Inc.
(SSII) is pulling ahead at 105. 7% versus -27. 1% for Masimo Corporation (MASI). On earnings-per-share growth, the picture is similar: Masimo Corporation grew EPS 51. 0% year-over-year, compared to 21. 2% for Vicarious Surgical Inc.. Over a 3-year CAGR, SSII leads at 207. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SSII or RBOT or ISRG or MASI or MDT?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -28. 5% for SS Innovations International, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -19. 2% for SSII. At the gross margin level — before operating expenses — ISRG leads at 66. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SSII or RBOT or ISRG or MASI or MDT more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Intuitive Surgical, Inc. (ISRG) is the more undervalued stock at a PEG of 2. 01x versus Medtronic plc's 36. 00x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 29. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDT: 40. 5% to $109. 50.
08Which pays a better dividend — SSII or RBOT or ISRG or MASI or MDT?
In this comparison, MDT (3.
6% yield) pays a dividend. SSII, RBOT, ISRG, MASI do not pay a meaningful dividend and should not be held primarily for income.
09Is SSII or RBOT or ISRG or MASI or MDT better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
47), 3. 6% yield). Vicarious Surgical Inc. (RBOT) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, RBOT: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SSII and RBOT and ISRG and MASI and MDT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SSII is a small-cap high-growth stock; RBOT is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; MASI is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while SSII, RBOT, ISRG, MASI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.